Pages that link to "Q38835745"
Jump to navigation
Jump to search
The following pages link to Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma (Q38835745):
Displaying 50 items.
- Contemporary Treatment of Metastatic Renal Cell Carcinoma (Q26740594) (← links)
- Sunitinib: the antiangiogenic effects and beyond (Q28066499) (← links)
- The Receptor Tyrosine Kinase AXL in Cancer Progression (Q28068756) (← links)
- Cabozantinib in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience (Q28072166) (← links)
- Renal cell carcinoma (Q30235364) (← links)
- AXL-Mediated Productive Infection of Human Endothelial Cells by Zika Virus (Q30275881) (← links)
- Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study (Q33441170) (← links)
- Clear Cell Renal Cell Carcinoma is linked to Epithelial-to-Mesenchymal Transition and to Fibrosis (Q33800254) (← links)
- Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. (Q36281483) (← links)
- Gas6/Axl Axis Contributes to Chemoresistance and Metastasis in Breast Cancer through Akt/GSK-3β/β-catenin Signaling (Q36970393) (← links)
- New treatment options for metastatic renal cell carcinoma with prior anti-angiogenesis therapy (Q37620907) (← links)
- Expression of microRNA-30c via lentivirus vector inhibits the proliferation and enhances the sensitivity of highly aggressive ccRCC Caki-1 cells to anticancer agents (Q37629578) (← links)
- Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma (Q37672483) (← links)
- Tyro3 carboxyl terminal region confers stability and contains the autophosphorylation sites (Q38698452) (← links)
- AXL receptor signalling suppresses p53 in melanoma through stabilization of the MDMX-MDM2 complex (Q38727237) (← links)
- Giving AXL the axe: targeting AXL in human malignancy (Q38772267) (← links)
- Emerging growth factor receptor antagonists for the treatment of renal cell carcinoma (Q38815893) (← links)
- Kinomic profiling identifies focal adhesion kinase 1 as a therapeutic target in advanced clear cell renal cell carcinoma (Q38832513) (← links)
- Upregulation of MARCKS in kidney cancer and its potential as a therapeutic target (Q38976447) (← links)
- Clinical Pharmacokinetics and Pharmacodynamics of Cabozantinib (Q38979283) (← links)
- Cabozantinib for the treatment of renal cell carcinoma (Q39005403) (← links)
- Cabozantinib: A Review in Advanced Renal Cell Carcinoma (Q39026733) (← links)
- Sunitinib in kidney cancer: 10 years of experience and development. (Q39038214) (← links)
- Strategies to overcome therapeutic resistance in renal cell carcinoma (Q39089402) (← links)
- Key Roles of AXL and MER Receptor Tyrosine Kinases in Resistance to Multiple Anticancer Therapies (Q39157476) (← links)
- Moving beyond vascular endothelial growth factor-targeted therapy in renal cell cancer: latest evidence and therapeutic implications (Q39296942) (← links)
- Niclosamide suppresses renal cell carcinoma by inhibiting Wnt/β-catenin and inducing mitochondrial dysfunctions (Q39367715) (← links)
- Targeting AXL overcomes resistance to docetaxel therapy in advanced prostate cancer (Q41093141) (← links)
- Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: A network meta-analysis of progression-free survival and overall survival in second line treatment of advanced renal cell carcinoma. (Q41491779) (← links)
- Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma. (Q41897121) (← links)
- Cabozantinib in metastatic renal cell carcinoma: latest findings and clinical potential (Q42257155) (← links)
- From Resistance to Sensitivity: Insights and Implications of Biphasic Modulation of Autophagy by Sunitinib. (Q42700492) (← links)
- Practical management of adverse events associated with cabozantinib treatment in patients with renal-cell carcinoma (Q45329617) (← links)
- Renal-Cell Cancer--Targeting an Immune Checkpoint or Multiple Kinases (Q46095927) (← links)
- A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma (Q46242867) (← links)
- Novel concepts of antiangiogenic therapies in metastatic renal cell cancer (Q47144667) (← links)
- Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression (Q47177700) (← links)
- Vitamin K epoxide reductase expression and prostate cancer risk (Q47596129) (← links)
- EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming (Q47600932) (← links)
- Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial. (Q47645332) (← links)
- Treatment of renal cell carcinoma: Current status and future directions (Q47726014) (← links)
- Treatment options after sorafenib failure in patients with hepatocellular carcinoma. (Q47832831) (← links)
- Hypoxia inducible factor (HIF) in the tumor microenvironment: friend or foe? (Q47893488) (← links)
- Second-line systemic therapy in metastatic renal-cell carcinoma: A review (Q47957574) (← links)
- Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors. (Q48243258) (← links)
- ARRDC1 and ARRDC3 act as tumor suppressors in renal cell carcinoma by facilitating YAP1 degradation (Q49236278) (← links)
- Expression of tyrosine kinase receptor AXL is associated with worse outcome of metastatic renal cell carcinomas treated with sunitinib. (Q49550673) (← links)
- Management of Adverse Events Associated with Cabozantinib Therapy in Renal Cell Carcinoma (Q49953442) (← links)
- Targeting AXL and mTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small-Cell Lung Cancer. (Q50896526) (← links)
- Current and Emerging Therapeutic Targets for Metastatic Renal Cell Carcinoma. (Q52611170) (← links)